When DFMO was combined with a polyamine transport inhibitor, AMXT 1501, to further address resistance to ODC1 inhibition, this combination resulted in the decreased growth of neuroblastoma cell lines in vitro and in vivo for TH-MYCN transgenic mice [34,37]. Here, MYCN is linked to neuroblastoma.